Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective,observational study to evaluate post-approval safety survillance of Tofacitinib in patients with Rheumatoid arthritis: data from US based Corrona Rheumatoid arthritis registry

Trial Profile

A prospective,observational study to evaluate post-approval safety survillance of Tofacitinib in patients with Rheumatoid arthritis: data from US based Corrona Rheumatoid arthritis registry

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Tofacitinib (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Oct 2018 Results assessing efficacy outcomes between 11 mg QD and 5 mg BID doses (n=334) presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 24 Oct 2018 Five-Year Results (n=10478) presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 07 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top